Circulating adhesion molecules as prognostic factors for cutaneous melanoma

Schaider, Helmut; Rech-Weichselbraun, Irene; Richtig, Erika; Seidl, Hannes; Soyer, H. Peter; Smolle, Josef; Kerl, Helmut

doi:10.1016/s0190-9622(97)70282-2

Cited by 15 publications

(9 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our data would suggest that high serum levels of solCD44s might be a positive prognostic factor for malignant melanoma patients. We therefore concur with the conclusion of Schaider et al (1997) that malignant melanoma patients with high serum levels of solCD44s should be studied in more detail.…”

Section: Discussionsupporting

confidence: 90%

“…In contrast, no signi®cant elevation was found in sera from melanoma patients, although some primary and metastatic malignant melanoma patients showed high levels of solCD44s (Schaider et al, 1997). Our data would suggest that high serum levels of solCD44s might be a positive prognostic factor for malignant melanoma patients.…”

Section: Discussioncontrasting

confidence: 52%

“…After subcutaneous transplantation of mammary carcinomas, levels of shedded human CD44 in the serum of mice correlated with tumor size (Fichtner et al, 1997). In the case of melanoma, serum levels of solCD44s and solCD44v were not signi®cantly elevated, although increased levels of solCD44s were detected in the serum of some patients with primary and metastatic malignant melanoma (Schaider et al, 1997).…”

Section: Introductionmentioning

confidence: 86%

See 2 more Smart Citations

Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid

et al. 2001

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

Section: Discussioncontrasting

confidence: 52%

Section: Introductionmentioning

confidence: 86%

See 1 more Smart Citation

Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid

et al. 2001

View full text Add to dashboard Cite

“…For detection and monitoring of metastases, clinical and radiological procedures are widely used. Laboratory tests have been developed to improve diagnosis including serum lactate dehydrogenase, 5-S-cysteinyl-3,4-dihydroxyphenylalanine, neuronspeci®c enolase and soluble intercellular adhesion molecule 1 (Banfalvi et al 1999;Couvrer et al 1993;Hirai et al 1997;KaÈ rnell et al 1997;Schaider et al 1997;Wollina et al 1998). S100 is a dimeric calcium-binding protein of 21 kDa composed of a and b subunits.…”

Section: Introductionmentioning

confidence: 99%

Serum protein S100β in patients with malignant melanoma detected by an immunoluminometric assay

Wollina¹,

Karte²,

Hipler³

et al. 2000

Journal of Cancer Research and Clinical Oncology

View full text Add to dashboard Cite

S100 protein is well established as a diagnostic tool in malignant melanoma immunohistology. In this study we measured S100beta in serum with a recently developed luminometric immunoassay with a detection limit of 0.02 microg/l. By measuring S-100beta in a group of apparently healthy individuals a mean value of 0.031 +/- 0.026 microg/l was found. In the reference group, serum S100beta was below 0.12 microg/l in all cases. To assess the sensitivity of the assay we investigated serum S-100beta levels in 371 serum samples of 315 patients with histological proven malignant melanoma at different disease stages. Staging was performed according to the German Society of Dermatology classification. Significant differences were observed between the control group and stages IIb (P = 0.01) and IV (P = 0.001). In tumour-bearing patients of stages IIIb and IV, the difference was highly significant (P < 0.0001). S100beta > 0.20 microg/l helps to distinguish between tumour-free and tumour-bearing patients with a specificity of 97.0% and a sensitivity of 64.6%. Our results demonstrate the serum S100beta is of limited value as a melanoma marker. However, it has clinical significance for identifying tumour-positive patients in advanced malignant melanoma stages III and IV.

show abstract

“…However, a large study from Austria [24]clearly demonstrated that none of the adhesion molecules measured (CD44 standard and isoforms, intercellular adhesion molecule-1, platelet/endothelial cell adhesion molecule-1) were significantly elevated and of prognostic value in any of the melanoma subgroups studied. Furthermore, control patients with inflammatory skin diseases as well as healthy volunteers could not routinely be distinguished from melanoma patients with regard to blood levels of circulating adhesion molecules [24]. …”

Section: Discussionmentioning

confidence: 99%

S100B Protein Detection in Serum Is a Significant Prognostic Factor in Metastatic Melanoma

et al. 1999

View full text Add to dashboard Cite

The serum detection of S100B, a new melanoma marker, has shown clinical significance in early studies. The aim of our study of 1,339 serum samples from 412 different melanoma patients and 107 control patients was to prove the prognostic value of serum S100B levels in melanoma patients at different stages of disease and at follow-up (median: 30 months). Using a cutoff level of 0.2 μg/l S100B, 5 of 286 patients (1.7%) with primary tumors (stage I/II), 14/73 (19.2%) patients with locoregional metastasis (stage III) and 57/84 (67.9%) patients with advanced disease (stage IV) were S100B positive (statistically significant differences for stage I/II vs. III, I/II vs. IV, and III vs. IV, p < 0.001). The estimated overall survival time was significantly longer (p < 0.001) for patients with S100B values below 0.2 μg/l compared to patients with elevated S100B levels (≥0.2 μg/l), which was independent of the stage of disease (I–IV). Regarding prognosis, we were furthermore able to distinguish different subgroups among stage III and IV patients using S100B serum levels (p < 0.01). Patients with different cutaneous non-melanoma diseases served as S100B-negative controls. S100B serum evaluations using the Sangtec^®100 IRMA are highly specific and sensitive for the detection of metastatic melanoma. S100B has been shown to be a relevant prognostic factor for survival in a study with a large sample size of melanoma patients including close follow-up evaluations.

show abstract

Circulating adhesion molecules as prognostic factors for cutaneous melanoma

Cited by 15 publications

References 10 publications

Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid

Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid

Serum protein S100β in patients with malignant melanoma detected by an immunoluminometric assay

S100B Protein Detection in Serum Is a Significant Prognostic Factor in Metastatic Melanoma

Contact Info

Product

Resources

About